INNOVENT BIO(01801.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.25 billion, YoY increase of 50.2%

NewTimeSpace News: August 25, 2026, INNOVENT BIO(01801.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 8.62 billion, increased by 44.76% YoY; Net Profit stood at CNY 1.25 billion, YoY increase of 50.2%; Profit Attributable to Shareholders stood at CNY 1.25 billion, YoY increase of 50.2%; Basic Earnings Per Share (EPS) stood at CNY 0.73.

In terms of profitability, INNOVENT BIO Gross Profit changed from CNY 5.12 billion in the same period last year to CNY 7.32 billion in the current period, increased by CNY 2.2 billion; gross profit margin changed from 86% in the same period last year to 84.96% in the current period, decreased by 1.04 percentage points; net profit changed from CNY 834.32 million in the same period last year to CNY 1.25 billion in the current period, increased by CNY 418.82 million; net profit margin changed from 14.01% in the same period last year to 14.54% in the current period, increased by 0.53 percentage points. 

In terms of earnings quality, INNOVENT BIO Operating Profit changed from CNY 981.94 million in the same period last year to CNY 1.69 billion in the current period, increased by CNY 712.54 million; Operating Profit Margin changed from 16.49% in the same period last year to 19.66% in the current period, increased by 3.17 percentage points. 

In terms of financial soundness, INNOVENT BIO Debt-to-Asset Ratio changed from 38.88% in the same period last year to 50.15% in the current period, increased by 11.27 percentage points; Total Equity changed from CNY 14.422 billion in the same period last year to CNY 20.746 billion in the current period, increased by CNY 6.32 billion; Current Liabilities changed from CNY 5.01 billion in the same period last year to CNY 9.32 billion in the current period, increased by CNY 4.31 billion; Quick Ratio changed from 2.39 in the same period last year to 2.48 in the current period, increased by 0.09 percentage points. 

In terms of R&D investment focus, INNOVENT BIO R&D Expenses changed from CNY 1.01 billion in the same period last year to CNY 1.68 billion in the current period, increased by CNY 674.91 million; R&D to Total Revenue Ratio changed from 16.95% in the same period last year to 19.54% in the current period, increased by 2.59 percentage points. 

By the close of trading on August 25, 2026, INNOVENT BIO(01801) saw a gain of 0.6% in its share price, closing at HKD 100.1. During the session, it reached an intraday high of HKD 101.3. The full-day turnover stood at HKD 1.22 billion, with the latest market capitalization at HKD 174.54 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.